184 related articles for article (PubMed ID: 29557529)
1. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.
Kiang TKL
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):509-531. PubMed ID: 29557529
[TBL] [Abstract][Full Text] [Related]
2. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui LR; Mansour H; Chahine EB
Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
[TBL] [Abstract][Full Text] [Related]
4. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
Feng HP; Vaddady P; Guo Z; Liu F; Panebianco D; Levine V; Caro L; Butterton JR; Iwamoto M; Yeh WW
Clin Transl Sci; 2017 Sep; 10(5):360-365. PubMed ID: 28625018
[TBL] [Abstract][Full Text] [Related]
5. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
Al-Salama ZT; Deeks ED
Drugs; 2017 May; 77(8):911-921. PubMed ID: 28417245
[TBL] [Abstract][Full Text] [Related]
6. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
[TBL] [Abstract][Full Text] [Related]
8. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
El Kassas M; Elbaz T; Abd El Latif Y; Esmat G
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1413-1421. PubMed ID: 27603877
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
Feng HP; Caro L; Fandozzi CM; Guo Z; Talaty J; Wolford D; Panebianco D; Iwamoto M; Butterton JR; Yeh WW
J Clin Pharmacol; 2018 May; 58(5):666-673. PubMed ID: 29329497
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
Sulejmani N; Jafri SM; Gordon SC
Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
[TBL] [Abstract][Full Text] [Related]
12. Elbasvir and grazoprevir for the treatment of hepatitis C.
Wang SJ; Huang CF; Yu ML
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
[No Abstract] [Full Text] [Related]
13. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
[TBL] [Abstract][Full Text] [Related]
15. US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
Boyd SD; Tracy L; Komatsu TE; Harrington PR; Viswanathan P; Murray J; Sherwat A
Clin Drug Investig; 2017 Apr; 37(4):317-326. PubMed ID: 28102520
[TBL] [Abstract][Full Text] [Related]
16. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
[TBL] [Abstract][Full Text] [Related]
18. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.
Landaverde C; Wells J; Hamner R; Goldstein JL
Expert Rev Gastroenterol Hepatol; 2016; 10(4):419-29. PubMed ID: 26818134
[TBL] [Abstract][Full Text] [Related]
19. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
Cheung TT; Yan Chiu JW; Yuen MF; Ling Lam KS; Yung Cheung BM; Feng HP; Yeh WW; Wang J; Li W; Zhao XM; Wang Z; Mu S
Clin Ther; 2018 May; 40(5):719-732.e1. PubMed ID: 29724498
[TBL] [Abstract][Full Text] [Related]
20. Elbasvir/Grazoprevir: First Global Approval.
Keating GM
Drugs; 2016 Apr; 76(5):617-24. PubMed ID: 26943930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
